openPR Logo
Press release

Hepatitis E Diagnostic Tests Market Predicted to Witness Surge in The Near Future

10-03-2017 08:20 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Hepatitis E Diagnostic Tests Market Predicted to Witness Surge

According to the research report, the global hepatitis E diagnostic tests market stood at US$43.7 mn in 2015. Expanding at a CAGR of 3.80% during the period from 2016 to 2024, the opportunity in this market is likely to increase to US$60.4 mn by the end of the forecast period. Being the primary test for the detection of hepatitis E, the kits used for ELISA HEV IgM tests have been the most valued diagnostic kits in this market in the recent past and will continue to be so due to the same reason.

Hepatitis E Hyperendemicity in Asian Economies to Ensure Dominance of Asia Pacific Region

The research report has also analyzed the worldwide market for hepatitis E diagnostic tests on the basis of geography. According to the study, Europe, Asia Pacific, Latin America, North America, and the Middle East and Africa have surfaced as the main regional markets for hepatitis E diagnostic tests across the world.

View and Download TOC of Hepatitis E Diagnostic Tests Market Research Report@ https://www.transparencymarketresearch.com/report-toc/16859

Due to the hyperendemicity of hepatitis E in various Asian economies, such as Nepal, Pakistan, India, Vietnam, Bangladesh, Bhutan, Burma, Kazakhstan, and Thailand, Asia Pacific has surfaced as the leading regional market for hepatitis E diagnostic tests and is expected to remain so over the forecast period. The Asia Pacific market for hepatitis E diagnostic tests is likely to acquire more than 48% of the overall market by 2024.

Besides, the Middle East and Africa is also projected to witness a significant rise in the market for the hepatitis E diagnostic tests over the next few years due to the increasing prevalence of hepatitis E in various countries in this region, such as Kenya, Morocco, Uganda, and Nigeria, owing to lack of safe drinking water and poor sanitation facilities.

Growing Prevalence of Hepatitis E to Boost Demand

“The growth of the global market for hepatitis E is directly proportional to the prevalence of hepatitis E across the world,” says the author of this study. As per the WHO, nearly 20 million people suffer from HEV infections every year, worldwide, among which around 3.3 million are symptomatic cases.

With the increasing scarcity of potable water and the lack of sanitation, the cases of hepatitis E infection is likely to increase considerably over the forthcoming years and will result in a substantial rise in the need for hepatitis E diagnostic test in the near future, states the research report.

Rising Incidence of Asymptomatic Diseases to Hamper Market’s Growth

Although the worldwide market for hepatitis E diagnostic tests currently looks teeming with opportunity, it may face a severe challenge over the years to come from the rising incidence of asymptomatic diseases, which are difficult to diagnose. The low level of awareness among consumers is also expected to emerge as a restraining factor for the growth of this market in the long run, notes the study.

Request and Download Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16859

Driven by a small number of players, the global market for hepatitis E diagnostic tests exhibits a highly competitive landscape, finds a new report by Transparency Market Research (TMR). With a share of nearly 31%, Beijing Wantai Biological Pharmacy led the global market in 2015 and was distantly followed by Mikrogen. Competitive pricing strategy among the leading players is expected to intensify the rivalry within the market in the forthcoming years.

Buy Full Hepatitis E Diagnostic Tests Market Report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=16859<ype=S

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatitis E Diagnostic Tests Market Predicted to Witness Surge in The Near Future here

News-ID: 750893 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Hepatitis

Is Hepatitis A Vaccine Required?
Hepatitis A Vaccine Market describes its growth, size, share, Forecast and trends to 2025 Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available
Hepatitis Drugs Market Is Growing Due to Increasing R&D Investments on Hepatitis …
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest
Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B In …
Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and
Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth
Global Hepatitis E Diagnostic Tests Market: Snapshot The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. There is increasing prevalence of hepatitis E in resource-limited region, such as various countries of Asia Pacific. The people of these regions suffer with frequent water contamination and have limited access to sanitation and hygiene,
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each